SNU-387 Cells

The SNU-387 cell line is derived from a human hepatocellular carcinoma (HCC) and is widely utilized in liver cancer research. This cell line provides a valuable model for studying the molecular and cellular mechanisms of hepatocarcinogenesis, tumor progression, and therapeutic responses. Hepatocellular carcinoma is one of the most common and lethal forms of liver cancer, making cell lines like SNU-387 essential for advancing our understanding of the disease and developing effective treatments.
SNU-387 cells exhibit an epithelial morphology and express markers typical of liver cancer, such as alpha-fetoprotein (AFP) and hepatocyte-specific antigens. They are characterized by genetic and epigenetic alterations common in HCC, including mutations in key oncogenes and tumor suppressor genes. Researchers use SNU-387 cells to investigate signaling pathways involved in liver cancer, such as the Wnt/β-catenin, PI3K/Akt, and MAPK pathways. These cells are also employed in high-throughput drug screening assays and preclinical testing of chemotherapeutic agents and targeted therapies. Additionally, SNU-387 cells are used to study the mechanisms of drug resistance and to develop strategies to overcome it. The relevance of the SNU-387 cell line in hepatocellular carcinoma research highlights its importance in advancing our knowledge of liver cancer biology and in the development of new therapeutic approaches for HCC patients.